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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B 
and Lactobacillus gasseri 57C and defence against vaginal pathogens 
(ID 934, further assessment) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) No 1924/2006 
in the framework of further assessment related to a combination of Lactobacillus fermentum 57A, Lactobacillus 
plantarum 57B and Lactobacillus gasseri 57C and defence against vaginal pathogens. The food constituent that 
is the subject of the claim, a combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and 
Lactobacillus gasseri 57C, is sufficiently characterised. The claimed effect, defence against vaginal pathogens, is 
a beneficial physiological effect. The target population is the female population. No human intervention studies 
were provided from which conclusions could be drawn for the scientific substantiation of the claim. On the basis 
of the data presented, the Panel concludes that a cause and effect relationship has not been established between 
the consumption of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C 
and defence against vaginal pathogens.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a certain 
number of Article 13 health claims would be eligible for further assessment by EFSA in order to be 
able to take a final decision on whether or not to include these claims in the list of permitted health 
claims. This opinion addresses the scientific substantiation of a health claim in relation to a 
combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus 
gasseri 57C and defence against vaginal pathogens. The scientific substantiation is based on the 
information provided by the competent Authority of Poland for further assessment of this claim. 
The food constituent that is the subject of the health claim is a combination of Lactobacillus 
fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C. The Panel considers 
that the combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus 
gasseri 57C is sufficiently characterised. 
The claimed effect, which is proposed for further assessment, is “a beneficial effect on vaginal 
bacterial flora increasing total number of Lactobacillus rods, colonisation with tested strains and 
decreasing pH value and Nugent score”. The proposed target population is “women with no symptoms 
of urogenital tract infections but with disturbed or abnormal vaginal flora”. The Panel notes that the 
claimed effect refers to defence against vaginal pathogens by increasing the number of lactobacilli 
and/or decreasing potentially pathogenic bacteria, and that the target population is the female 
population. The Panel considers that defence against vaginal pathogens is a beneficial physiological 
effect.  
The only human intervention study provided which investigated the effect of a combination of 
Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C on 
defence against vaginal pathogens was an uncontrolled study. The Panel notes that no conclusions can 
be drawn from an uncontrolled study for the scientific substantiation of the claim. 
The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim and animal and in vitro studies cannot predict the 
occurrence of an effect of a combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 
57B and Lactobacillus gasseri 57C on defence against vaginal pathogens in vivo in humans. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of Lactobacillus fermentum 57A, 
Lactobacillus plantarum 57B and Lactobacillus gasseri 57C and defence against vaginal pathogens. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that a combination of Lactobacillus fermentum 57A, 
Lactobacillus plantarum 57B and Lactobacillus gasseri 57C, which is the subject of the health claim, 
is not sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 
2009), EFSA received additional information from the competent Authority of Poland for further 
assessment of this claim. The information provided in the framework of further assessment for the 
health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 934) 
The food constituent that is the subject of the health claim is a combination of Lactobacillus 
fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C. 
For Lactobacillus fermentum 57A (hereafter L. fermentum 57A) a culture collection number from the 
Polish Collection of Microorganisms (PCM) (no. B/00007) was provided. The PCM has the status of 
International Depositary Authority under the Budapest Treaty. Data on the identification and 
characterisation of L. fermentum 57A at species and strain level using both phenotypic (colony 
morphology, carbohydrates fermentation and antibiotic resistance profiles) and genotypic (16S rRNA 
gene sequence analysis and 16S/23S intergenic spacer region sequence analysis, species-specific PCR, 
RAPD and PFGE) methods were provided in the application and accompanying references (Heczko, 
2006, unpublished, 2008, unpublished; Pałucha, 2010, unpublished; Strus, 2010, unpublished). The 
Panel considers that L. fermentum 57A is sufficiently characterised. 
For Lactobacillus plantarum 57B (hereafter L. plantarum 57B) a culture collection number from the 
PCM (no. B/00008) was provided. Data on the identification and characterisation of L. plantarum 57B 
at species and strain level using both phenotypic (colony morphology, carbohydrates fermentation and 
antibiotic resistance profiles) and genotypic (16S rRNA gene sequence analysis and 16S/23S 
intergenic spacer region sequence analysis, species-specific PCR, RAPD, PFGE and MLST) methods 
were provided in the application and accompanying references (Heczko, 2006, unpublished, 2008, 
unpublished; Pałucha, 2010, unpublished; Strus, 2010, unpublished). The Panel considers that 
L. plantarum 57B is sufficiently characterised. 
For Lactobacillus gasseri 57C (hereafter L. gasseri 57C) a culture collection number from the PCM 
(no. B/00009) was provided. Data on the identification and characterisation of L. gasseri 57C at 
species and strain level using both phenotypic (colony morphology, carbohydrates fermentation and 
antibiotic resistance profiles) and genotypic (16S rRNA gene sequence analysis and 16S/23S 
intergenic spacer region sequence analysis, species-specific PCR, RAPD and PFGE) methods were 
provided in the application and accompanying references (Heczko, 2006, unpublished, 2008, 
unpublished; Pałucha, 2010, unpublished; Strus, 2010, unpublished). The Panel considers that 
L. gasseri 57C is sufficiently characterised. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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The formulation, which is the subject of the claim, is the three bacterial strains in a ratio of L. gasseri 
57C 50 %, L. fermentum 57A 25 %, and L. plantarum 57B 25 %. 
The Panel considers that the food constituent, a combination of Lactobacillus fermentum 57A, 
Lactobacillus plantarum 57B and Lactobacillus gasseri 57C, which is the subject of the health claim, 
is sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 934) 
The claimed effect, which is proposed for further assessment, is “a beneficial effect on vaginal 
bacterial flora increasing total number of Lactobacillus rods, colonisation with tested strains and 
decreasing pH value and Nugent score”. The proposed target population is “women with no symptoms 
of urogenital tract infections but with disturbed or abnormal vaginal flora”.  
The Panel notes that the claimed effect refers to defence against vaginal pathogens by increasing the 
number of lactobacilli and/or decreasing potentially pathogenic bacteria, and that the target population 
is the female population. 
Unlike any other anatomical site of the body, most vaginal vaults are dominated by one or more 
species of Lactobacillus. In over 70 % of women, vaginal microbiota are dominated by lactobacilli 
(>50 %) (Ling et al., 2010; Ravel et al., 2010; Yamamoto et al., 2009). This microbiota is different 
from the more complex gut microbiota, where lactobacilli represent less than 3 % of the bacterial 
population (Franks et al., 1998; Lay et al., 2005; Sghir et al., 2000). The diagnosis of bacterial 
vaginosis (BV) can be based on, for example, the Nugent score (microscopic examination of Gram 
stained smear or vaginal discharge for bacteria and „clue‟ cells). The Panel notes that appropriate 
outcome measures of the claimed effect include assessment of the changes in the Nugent scores. 
Nugent scores are estimated by measuring the relative amounts of lactobacilli and bacterial pathogens 
present in the vagina. A Nugent score of 0-3 is classified as normal (lactobacilli are present, but not 
Gardnerella/Bacteroides or curved Gram-negative bacilli), a score of 4-6 as intermediate (colonisation 
by Gardnerella/Bacteroides and curved Gram-variable rods (Mobiluncus)), and a score of 7-10 is 
indicative of BV (with domination of Gardnerella/Bacteroides or curved Gram-negative bacilli and 
absence of lactobacilli). 
The Panel considers that defence against vaginal pathogens is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 934) 
The references provided for the scientific substantiation of the claim included textbooks, narrative 
reviews, industrial certifications and consensus documents that did not provide original data for the 
scientific substantiation of the claim. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
Among six human studies provided, four did not use the combination of bacterial strains which is the 
subject of the claim (Caillouette et al., 1997; Priestley et al., 1997; Samet et al., 2003; Vasquez et al., 
2002). The Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claim. 
Two references described the same human study (Strus et al., 2008; Strus et al., 2011, unpublished). In 
an open-label, not randomised, uncontrolled study the combination of the three bacterial strains which 
is the subject of the claim,was administered orally (1×10
9
 CFU/day of lactic acid bacteria in the ratio: 
L. gasseri 57C 50 %, L. fermentum 57A 25 %, L. plantarum 57B 25 %) for 60 days to a group of 
outpatient women with intermediate Nugent score and increased vaginal pH but without clinical 
symptoms of urogenital infection to evaluate the colonisation of the vaginal epithelium by at least one 
of the given strains. The secondary endpoints included measurement of numbers of total lactobacilli in 
the vagina and rectum, vaginal pH, and Nugent score values. The Panel notes that this study was a 
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preliminary, open-label, uncontrolled study and considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. 
The animal and in vitro studies provided evaluated bacterial adhesion properties, bacterial binding to 
cell surfaces, production of hydrogen peroxide by bacteria, bacterial resistance to gastric acid and bile 
salts, and bactericidal activity. The Panel notes that no human intervention studies were provided from 
which conclusions could be drawn for the scientific substantiation of the claim. The Panel notes that 
animal and in vitro studies cannot predict the occurrence of an effect of a combination of 
Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C on 
defence against vaginal pathogens in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and 
Lactobacillus gasseri 57C and defence against vaginal pathogens. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of Lactobacillus fermentum 57A, Lactobacillus 
plantarum 57B and Lactobacillus gasseri 57C, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect proposed for further assessment is “a beneficial effect on vaginal bacterial 
flora increasing total number of Lactobacillus rods, colonisation with tested strains and 
decreasing pH value and Nugent score”. The target population is the female population. 
Defence against vaginal pathogens is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and 
Lactobacillus gasseri 57C and defence against vaginal pathogens. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00129). The scientific substantiation is based on the information provided by the 
competent Authority of Poland for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
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 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1.  Health claims related to a combination of Lactobacillus fermentum 57A, 
Lactobacillus plantarum 57B and Lactobacillus gasseri 57C, including conditions of use, as proposed 
in the framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
934 A combination of 3 bacterial 
strains: Lactobacillus 
fermentum 57A, Lactobacillus 
plantarum 57B and 
Lactobacillus gasseri 57C  
A beneficial effect on 
vaginal bacterial flora 
increasing total number of 
Lactobacillus rods, 
colonization with tested 
strains and decreasing pH 
value and Nugent score. 
Exerts a beneficial effect on 
vaginal bacterial flora 
increasing total number of 
Lactobacillus rods and 
decreasing pH value. 
Conditions of use 
Once daily for at least 20 days, 1 capsule of the product contains not less than 10
8
 CFU of the 
combination of strains: Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and 
Lactobacillus gasseri 57C and excipients.  
Intended for women with no symptoms of urogenital tract infections but with disturbed or 
abnormal vaginal flora i.e. in situations which are characterised by increased vaginal pH and 
Nugent score as well as a decreased number of lactobacilli.  
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GLOSSARY AND ABBREVIATIONS 
BV  Bacterial vaginosis 
CFU  Colony forming units 
DNA  Deoxyribonucleic acid 
MLST  Multilocus sequence typing 
PCM  Polish Collection of Microorganisms 
PCR  Polymerase chain reaction 
PFGE  Pulsed field gel electrophoresis 
RAPD  Random amplification of polymorphic DNA 
rRNA  Ribosomal ribonucleic acid 
 
 
 
